Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 in Moderate-to-Severe Atopic Dermatitis Ib/IIa Trial
CTR20213221Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM326 in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Dec 2021; status: completed.
02
Drugs
CM326
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20213221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213221.